Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
Urges everyone to follow COVID Appropriate Behaviour and curb any misinformation
To enable company to be future-ready by tapping potential in CDMO space
Bourgoin early development hub broadens offerings for oral solid dose formulations
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
The milestone of operating continuously a very complex system for over two years has demonstrated the effectiveness of integrated laboratory automation solutions
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Subscribe To Our Newsletter & Stay Updated
